ADC Therapeutics SA - notizie pubblicate 183 - letture 4.623
ADC THERAPEUTICS SA
Regulation FD Presentation - Form 8-K
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
2024 Research Investor Event
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer adc therapeutics sa ...
ADC THERAPEUTICS SA
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
View all news adc therapeutics announces updates on lotis-7 clinical trial evaluating zynlonta® in combination with glofitamab or mosunetuzumab in patients with relapsed/refractor ...
ADC THERAPEUTICS SA
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
View all news adc therapeutics to host a virtual research investor event on tuesday, april 9, 2024 april 03, 2024 lausanne, switzerland, april 03, 2024 (globe newswire) -- adc ther ...
ADC THERAPEUTICS SA
Supplemental Prospectus - Form 424B3
Filed pursuant to rule 424(b)(3) registration no. 333-267295 prospectus adc therapeutics sa 1,260,863 common shares pursuant to this prospectus, the selling shareholders may offer ...
ADC THERAPEUTICS SA
Supplemental Prospectus - Form 424B3
Filed pursuant to rule 424(b)(3) registration no. 333-267293 prospectus adc therapeutics sa 4,412,840 common shares pursuant to this prospectus, the selling shareholders may offer ...
ADC THERAPEUTICS SA
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: march 14, 2024 accession number: 0000950 ...
ADC THERAPEUTICS SA
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: march 14, 2024 accession number: 0000950 ...
ADC THERAPEUTICS SA
Notice of Effectiveness - Form EFFECT
Notice of effectiveness united states securities and exchange commission washington, d.c. 20549 notice of effectiveness effectiveness date: march 14, 2024 accession number: 0000950 ...
ADC THERAPEUTICS SA
Post-Effective Amendment to Registration Statement - Form POS AM
As filed with the securities and exchange commission on march 13, 2024. registration no. 333-270570 united states securities and exchange commission washington, d.c. 20549 post-eff ...
ADC THERAPEUTICS SA
Post-Effective Amendment to Registration Statement - Form POS AM
As filed with the securities and exchange commission on march 13, 2024. registration no. 333-267295 united states securities and exchange commission washington, d.c. 20549 post-eff ...
ADC THERAPEUTICS SA
Post-Effective Amendment to Registration Statement - Form POS AM
As filed with the securities and exchange commission on march 13, 2024. registration no. 333-267293 united states securities and exchange commission washington, d.c. 20549 post-eff ...
ADC THERAPEUTICS SA
Annual Report - Form ARS
The text version of this document is not available. you can access the original document here. attachments original link permalink disclaimer adc therapeutics sa published this con ...
ADC THERAPEUTICS SA
Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)
Adc-20231231 table of contents united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the ...
ADC THERAPEUTICS SA
ADCT Q4 Earnings
4q 2023 earnings call march 13, 2024 forward-looking statements this presentation and any accompanying oral presentation have been prepared by adc therapeutics sa ("adc therap ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti